Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "ABI"

3664 News Found

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
News | August 03, 2025

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results


Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India
News | August 02, 2025

Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India

The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements


Fermenta receives CEP by EDQM for Vitadee 100 SD
Biotech | August 01, 2025

Fermenta receives CEP by EDQM for Vitadee 100 SD

Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3


iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025
News | August 01, 2025

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide


Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
News | August 01, 2025

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY


Aurobindo to acquire Lannett Company for Rs. 2,185 Cr
News | July 31, 2025

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities


Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
News | July 31, 2025

Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU

Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne


Maziar Mike Doustdar appointed President and CEO of Novo Nordisk
People | July 31, 2025

Maziar Mike Doustdar appointed President and CEO of Novo Nordisk

Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit